FcεR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells

Blood

Volumn 107, Issue 2, 2006, Pages 610-618

  Qiao, Huihong ^a   Andrade, Marcus V ^a   Lisboa, Felipe A ^a   Morgan, Katrina ^a   Beaven, Michael A ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; CALCIUM; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; LIGAND; LIPOPOLYSACCHARIDE; PROTEIN KINASE;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; DEGRANULATION; GENETICS; IMMUNOLOGY; METABOLISM; SECRETION;

ANIMALS; ARACHIDONIC ACID; CALCIUM; CALCIUM SIGNALING; CELL DEGRANULATION; CELLS, CULTURED; CYTOKINES; ENZYME ACTIVATION; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIGANDS; LIPOPOLYSACCHARIDES; MAST CELLS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; RECEPTORS, IGE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 30444446822     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2271     Document Type: Article

References (66)

1. CDC US. Forecasted state-specific estimates of self reported asthma prevalence - United States. MMWR Morb Mortal Wkly Rep. 1998;47:1022-1025.
2. Beaven MA, Hundley TR. Mast cell related diseases: genetics, signaling pathways, and novel therapies. In: Finkel TH, Gutkind JS, eds. Signal Transduction and Human Disease. Hoboken, NJ: John Wiley & Sons Inc; 2003:307-355.
3. Gern JE. Viral and bacterial infections in the development and progression of asthma. J Allergy Clin Immunol. 2000;105:S497-S502.
4. Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med. 2005;11:21-26.
5. Marsland BJ, Scanga CB, Kopf M, Le GG. Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells. Clin Exp Allergy. 2004;34:1299-1306.
6. Kondo Y, Matsuse H, Machida I, et al. Effects of primary and secondary low-grade respiratory syncytial virus infections in a murine model of asthma. Clin Exp Allergy. 2004;34:1307-1313.
7. Liu AH. Endotoxin exposure in allergy and asthma: reconciling a paradox. J Allergy Clin Immunol. 2002;109:379-392.
8. Reed CE, Milton DK. Endotoxin-stimulated innate immunity: a contributing factor for asthma. J Allergy Clin Immunol. 2001;108:157-166.
9. Basu S, Fenton MJ. Toll-like receptors: function and roles in lung disease. Am J Physiol Lung Cell Mol Physiol. 2004;286:L887-L892.
10. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004;5:975-979.
11. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398-401.
12. Haynes LM, Moore DD, Kurt-Jones EA, et al. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol. 2001;75:10730-10737.
13. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide- enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med. 2002;196:1645-1651.
14. Redecke V, Hacker H, Datta SK, et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol. 2004;172:2739-2743.
15. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
16. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257-263.
17. Aliprantis AO, Yang RB, Mark MR, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999;285:736-739.
18. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14.
19. McGettrick AF, O'Neill LA. The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol Immunol. 2004;41:577-582.
20. Beaven MA, Metzger H. Signal transduction by Fc receptors: the Fc epsilon RI case. Immunol Today. 1993;14:222-226.
21. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol. 2004;4:787-799.
22. Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002;109:1351-1359.
23. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6:135-142.
24. Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol. 2003;132:87-97.
25. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol. 2003;170:1625-1629.
26. Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol. 2003;33:899-906.
27. Ikeda T, Funaba M. Altered function of murine mast cells in response to lipopolysaccharide and peptidoglycan. Immunol Lett. 2003;88:21-26.
28. Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol. 2002;14:1065-1074.
29. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy Clin Immunol. 2004;114:174-182.
30. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol. 2004;173:531-541.
31. Rivera J. Molecular adapters in FcεRI signaling and the allergic response. Curr Opin Immunol. 2002;14:688-693.
32. 2+ and purified isozymes in washed permeabilized cells. J Biol Chem. 1993;268:1749-1756.
33. Zhang C, Baumgartner RA, Yamada K, Beaven MA. Mitogen activated protein (MAP) kinase regulates production of TNFα and release of arachidonic acid in mast cells: indications of communication between p38 and p42 MAP kinases. J Biol Chem. 1997;272:13397-13402.
34. Hundley TR, Gilfillan AM, Tkaczyk C, et al. Kit and FcεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood. 2004;104:2410-2417.
35. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996;15:2760-2770.
36. Raingeaud J, Gupta S, Rogers JS, et al. Proinflammatory cytokines and environmental stress cause p38-mitogen protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995;270:7420-7426.
37. Derijard B, Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025-1037.
38. van Dam H, Wilhelm D, Herr I, et al. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J. 1995;14:1798-1811.
39. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 1994;13:4361-4369.
40. Quelle FW, Shimoda K, Thierfelder W, et al. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol. 1995;15:3336-3343.
41. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1-24.
42. Schmitz ML, Bacher S, Kracht M. IκB-independent control of NF-κB activity by modulatory phosphorylations. Trends Biochem Sci. 2001;26:186-190.
43. 1-dependent pathway of FcεRI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase. J Biol Chem. 2003;278:48474-48484.
44. Andrade MV, Hiragun T, Beaven MA. Dexamethasone suppresses antigen-induced activation of phosphatidylinositol 3-kinase and downstream responses in mast cells. J Immunol. 2004;172:7254-7262.
45. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol. 2001;70:977-984.
46. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001;98:13681-13686.
47. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739-746.
48. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem. 1995;270:27489-27494.
49. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
50. Marson A, Lawn RM, Mikita T. Oxidized low density lipoprotein blocks lipopolysaccharide-induced interferon β synthesis in human macrophages by interfering with IRF3 activation. J Biol Chem. 2004;279:28781-28788.
51. Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate Toll-like receptor signaling in innate immune cells. J Biol Chem. 2004;279:54708-54715.
52. Lorentz A, Klopp I, Gebhardt T, Manns MP, Bischoff SC. Role of activator protein 1, nuclear factor-κB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol. 2003;111:1062-1068.
53. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol. 2002;169:3801-3810.
54. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol. 2002;2:773-786.
55. Wedemeyer J, Tsai M, Galli SJ. Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol. 2000;12:624-631.
56. 2 pathway in a rat mast cell line: indications of different pathways for release of arachidonic acid and secretory granules. J Immunol. 1995;154:5391-5402.
57. van Dam H, Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene. 2001;20:2453-2464.
58. Falvo JV, Uglialoro AM, Brinkman BM, et al. Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol Cell Biol. 2000;20:2239-2247.
59. Decker EL, Nehmann N, Kampen E, et al. Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic Acids Res. 2003;31:911-921.
60. Kwon J, Lee SJ, Benveniste EN. A 3′ cis-acting element is involved in tumor necrosis factor-α gene expression in astrocytes. J Biol Chem. 1996;271:22383-22390.
61. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol. 1996;16:459-467.
62. Kramer B, Wiegmann K, Kronke M. Regulation of the human TNF promoter by the transcription factor Ets. J Biol Chem. 1995;270:6577-6583.
63. Li DH, Kumanogoh A, Cao TM, Parnes JR, Cullen JM. Woodchuck interleukin-6 gene: structure, characterization, and biologic activity. Gene. 2004;342:157-164.
64. Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-κB, AP-1, and C/EBP. J Immunol. 2003;170:3099-3108.
65. Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20:2476-2489.
66. Mekori YA, Metcalfe DD. Mast cells in innate immunity. Immunol Rev. 2000;173:131-140.